Friday, Sept 21, 2018 from 11am-12pm
at Duke Cancer Institute Lower 00 Atrium
Host The Community
In 2016, the launch of the White House Cancer Moonshot galvanized a movement to double the rate of progress against cancer. Thousands of individuals and hundreds of organizations from across industries and sectors throughout the country convened to develop solutions and partnerships that are improving cancer outcomes and saving lives. Together, we made tremendous progress, but our work is not done.
So, on September 21, 2018, Biden Cancer Community Summits in Washington, D.C. and all across the country will focus national attention on the urgency to build on this momentum through community-driven action, ideas and solutions.
Local Solutions, National Narrative
The most effective, meaningful and sustainable solutions against cancer are grounded in the community’s realities. Each Biden Cancer Community Summit –
Creates an opportunity for you to share experiences and lessons, and most importantly, come together to map out actions needed to support cancer patients and families.
Provides the foundation for a cohesive national narrative that connects and scales ideas and approaches, to provoke action needed to accelerate progress in cancer research and care.
The CIFCF Biden Cancer Summit Hosted at
Duke Cancer Institute will drive local conversations and ignite community-driven action.
The Summit will include a featured lecture on "Targeted Cancer Therapies in Prostate & Urologic Cancers" including input from the patient perspective from Curtis Garbett, Founder of Crush It For Curtis Foundation, bladder cancer patient and targeted therapy recipient.
Jennifer Freedman, Ph.D. Assistant Professor of Medicine-Oncology, Member of the Duke Cancer Institute and Director of Operations for the Genitourinary Oncology Research Laboratory will deliver the aforementioned featured lecture, including current research and the innovative scientific pipeline.
The summit will also include a panel discussion with scientists, physician-scientists, and young scientists in training working on new targeted therapies for genitourinary cancers.